Sisu Global Announces New Appointment to Board of Directors 

August 14, 2020

FOR IMMEDIATE RELEASE

BALTIMORE, Md., August 14, 2020 -- Sisu Global is excited to announce the addition of Dr. Geoffrey Ling, MD, PhD to our Board of Directors. Dr. Ling is currently the Chief Technologist of Catalio Capital Management, Sisu’s largest institutional investor.  In addition to Dr. Ling’s impressive credentials, he has the context and the passion for how Hemafuse can change the quality of care in emergency situations.

Dr Ling is a retired U.S. Army Colonel having served 21 years on active duty. He was deployed to Afghanistan in 2003 and Iraq in 2005 and had four in-theater missions between 2009-2011 for the Joint Chiefs of Staff to assess TBI care in the combat theater. Through all of his trauma expertise, Dr. Ling has taken care of patients in situations where Hemafuse will be used in the future to improve the quality of care for our country's service members and for civilians.

Dr. Ling is also experienced in bringing cutting-edge technology from idea to market through his roles as the Founding Director of the Biological Technologies Office at DARPA and as the Assistant Director for Medical Innovation of the Science Division at the President Obama White House Office of Science and Technology Policy, Technology and Policy. 

“We are thrilled to welcome Dr. Geoffrey Ling as a new independent director to the Sisu Global board,” says Carolyn Yarina, Co-founder and CEO of Sisu Global. “Dr. Ling joins us at an exciting time, as Sisu is scaling Hemafuse into new markets to provide life-saving blood access to more patients. Dr. Ling will be providing direct oversight and guidance to the company as Sisu pursues US FDA clearance and will provide great value as Sisu plans to expand Hemafuse’s reach to service members of the military.”

Dr. Ling is presently the Professor of Neurology and Neuro Critical Care at Johns Hopkins and Professor of Neurology and Neuroscience at the Uniformed Services University of the Health Sciences. He Is CEO of Ling & Associates, LLC, a firm specializing in technology development for healthcare and On Demand Pharmaceuticals, a company developing a platform for  point-of-care medicine manufacturing. 

“I am pleased to join Sisu's Board of Directors because I believe in its beneficent mission, which is to provide a low cost effective method to recover and return blood from patients who are suffering from hemorrhagic shock,” said Dr. Ling. “The company's focus on the developing world where this is an especially severe condition is laudable.  The Hemafuse system's simplicity makes it a practical solution in this setting.”

MEDIA CONTACT

Alexis Taylor

Communications Specialist

alexis.taylor@sisuglobalhealth.com

Sisu Global

ABOUT SISU GLOBAL

Sisu Global (SisuGlobal.health) is a corporation headquartered in Baltimore, Maryland. We envision a world where medical technology enables access to healthcare in every community. Right now, 80% of the world’s medical devices are designed for 10% of the world’s population. Sisu aims to change this statistic by designing and scaling medical devices made specifically for the global market. Sisu is the manufacturer of goods including the Hemafuse™ System. For more information, please visit our website, SisuGlobal.health

ABOUT HEMAFUSE

The Hemafuse™ is a handheld, mechanical medical device for intraoperative autotransfusion of blood collected from an internal hemorrhage, meant to replace or augment donor blood in emergency situations. The Hemafuse™ is a device that can support the donor blood ecosystem by providing an option for clinicians to salvage and recycle a patient’s own blood in cases of internal bleeding. This immediate access to blood can shorten the wait time to perform surgery, increase hospital efficiency and provide access to blood where there may be no other option. This device was developed with invaluable feedback from Komfo Anokye Teaching Hospital and Korle Bu Teaching Hospital.